Trial Profile

A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Mar 2022 Results of post-hoc analysis assessing response according to background factors, published in the Journal of the Neurological Sciences.
15 Oct 2021 Results of post-hoc analysis assessing efficacy and safety of safinamide as an add-on therapy to a stable dose of levodopa in patients with PD who were experiencing wearing-off, published in the Journal of the Neurological Sciences.
22 Sep 2021 Results of post-hoc analysis assessing efficacy of safinamide for mood and pain, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com